Buy the Pullback: Celestica’s 90% Revenue Roadmap Is Real — Take a Measured Long Position

Hook + thesis

Celestica just delivered a Q3 print that reads like a growth company: revenues up sharply, adjusted EPS more than doubling, and management upgrading guidance into a very aggressive 2027 target. On 10/27/2026 Celestica reported Q3 adjusted EPS of $3.30 and revenue of $5.83 billion, roughly +82.5% year-over-year, and then raised 2026 revenue guidance to $21 billion while laying out a $40 billion target for 2027. That 2027 target implies roughly 90% growth and reframes Celestica from a steady EMS supplier into a strategic infrastructure partner for AI data centers.

That said, the market is rightfully wrestling with execution: management flagged larger working-capital needs and reduced 2026 free cash flow guidance to $460 million while planning $1.5B-$2.0B of capex to support the ramp. The pullback into the $250s after the run is an opportunity to own the thematic upside — but only with specific risk controls. This is a trade, not a blind buy-and-hold.

What Celestica does and why the market should care

Celestica is a global provider of supply-chain and manufacturing solutions to equipment manufacturers and service providers. It operates two segments: Advanced Technology Solutions (ATS) - covering aerospace, industrial, health tech and capital equipment - and Connectivity & Cloud Solutions (CCS), which includes enterprise communications, telecommunications, servers, and storage.

Investors should care because CCS is now an AI infrastructure play. The company reported CCS revenue growth of roughly 102% year-over-year in the quarter, driven by hyperscalers and AI labs ordering servers and storage capacity. That growth is the fundamental driver: large, multi-year deals from customers building AI clusters can move Celestica’s top line materially and change its growth profile from mid-single digits to multi-year doubling.

The numbers that matter

Use these as the factual backbone of the trade:

• Q3 revenue: $5.83 billion, up ~82.5% YoY (reported 10/27/2026).
• Q3 adjusted EPS: $3.30, +108.9% YoY, and above consensus by ~9.3%.
• 2026 guidance raised to $21 billion in revenue (management described this as ~69% growth on the year).
• 2027 management target: $40 billion in revenue (implies ~90% ramp from 2026 to 2027).
• 2026 free cash flow guidance cut to $460 million due to higher inventory and capex needs; company-level free cash flow shown at $545.4 million in trailing data.
• Market snapshot: current price $258.88, market cap approximately $32.6 billion, EV roughly $32.5 billion.
• Valuation multiples (recent): P/E roughly 28.6x, price-to-sales ~1.96x, EV/EBITDA ~19.18x.

Valuation framing

At roughly $258–$283 in recent prints and a market cap in the low $30 billions, Celestica is priced like a high-growth industrial: elevated multiples but not nosebleed compared with pure software growth names. The stock trades around 28.6x trailing earnings and ~1.96x price-to-sales, with EV/EBITDA near 19x. Those multiples reflect the market’s view that the company must convert huge revenue growth into durable margins and positive, scaled free cash flow.

Two valuation points to keep in mind:

• If Celestica hits management’s 2027 revenue and margin math, multiples would look modest relative to the growth profile because the revenue base would roughly double. In that scenario, earnings power and cash flow would expand materially and justify a re-rating.
• If execution stalls — margins compressed by rising input costs, or cash conversion lagging due to elevated inventory — the current multiple provides little cushion and a correction is likely. Management’s own cut in 2026 FCF guidance to $460M is a red flag that the growth-to-cash conversion is not linear.

Technical backdrop and sentiment

Short interest data shows active shorting but limited days-to-cover (~2 days recently), meaning momentum trades can move the stock quickly in either direction. The RSI sits around 36.7, indicating the shares have room for a mean reversion bounce after the pullback. Volume spikes on print days confirm this remains a news-driven trade.

Catalysts to watch (2-5)

• Quarterly updates confirming the conversion of backlog into revenue and normalizing working capital. Any quarterly beat on revenue/margins should re-rate the stock higher.
• Public disclosures of multi-year supply agreements with hyperscalers or multi-year bookings that illustrate durable demand.
• Proof points on capex execution that show the $1.5B-$2B plan is acquiring productive capacity rather than ballooning fixed costs.
• Stabilization or improvement in free cash flow and a narrowing gap between FCF guidance and reported FCF.

Trade plan (actionable)

Stance: Long.

Entry price: $260.00

Stop loss: $225.00

Primary target: $375.00

Time horizon: long term (180 trading days) - I expect this trade to play out over the next several quarters as management executes on capacity build, converts backlog and demonstrates cash conversion. The thesis depends on continued robust AI demand and visible progress converting revenue into operating leverage; 180 trading days gives time for two to three quarterly prints and for the market to re-rate the shares if execution is clean.

Why these levels?

• Entry $260 sits under recent intraday levels and offers a margin to the recent $282 print; it also aligns with the short-term technical band where RSI is showing oversold conditions.
• Stop $225 limits downside to roughly ~13% below entry and protects capital if the market re-prices Celestica on deteriorating cash flow or a surprise customer slowdown.
• Target $375 reflects a move back toward a mid-to-high multiple on a substantially larger revenue base; it is below the 52-week high of $474 and assumes a re-rate but not full reversion to peak multiples. If management confirms 2027 revenue and margin targets, the stock could move materially beyond $375, but that outcome is contingent on flawless execution.

Risks and counterarguments

Below are the primary risks and at least one explicit counterargument to the trade thesis.

• Working capital drag and lower FCF - Management cut 2026 free cash flow guidance to $460M citing elevated inventory and capital investment. If cash conversion remains weak as Celestica grows, the valuation premium is not justified.
• Execution risk on capex - The company plans $1.5B-$2B of capex to hit the 2027 $40B target. Large capex programs carry execution and timing risk that can compress margins and delay returns.
• Customer concentration - Rapid AI growth is often driven by a handful of hyperscalers. Any pause or re-prioritization at a major customer would disproportionately impact Celestica’s top line.
• Valuation sensitivity - The stock already trades at elevated multiples (P/E ~28.6x). If growth disappoints, multiple contraction could trigger meaningful downside even if revenue still grows.
• Macro / supply chain shocks - A slowdown in tech capex or renewed supply chain disruption could slow order flow and push product delivery timelines out, damaging both revenue and margins.

Counterargument: Critics will say Celestica’s 2027 $40B target is aspirational and that the market should discount the plan given the company’s reduced 2026 FCF outlook and capex needs. They argue the stock’s current premium is justified only if revenue growth quickly translates into stable margins and strong FCF — something management has yet to prove at scale.

What would change my mind

I would materially reduce conviction if any of the following occurs:

• Management retracts the $40B 2027 target or significantly trims 2026 revenue guidance.
• Reported free cash flow for 2026 or subsequent quarters disappoints consensus materially below the $460M guidance and shows a trend lower.
• We see cascading customer cancellations or meaningful lengthening of payment terms from key hyperscaler customers that materially impact working capital.
• Capex overruns push the company into a net-debt build or dilute shareholder returns meaningfully.

Conclusion and stance

Celestica’s Q3 print and the upgrade to a $40B 2027 target create a rare combination of top-line explosiveness and tangible operational risk. For disciplined traders, the recent pullback into the mid-$200s provides an actionable long opportunity with clear entry, stop and target levels. My stance is to buy on the dip with a long-term (180 trading days) horizon while strictly managing risk: the story will either be validated by continued revenue conversion and improving cash flow, or it will be exposed by execution/working-capital issues that tighten the margin of safety.

If Celestica proves it can scale capacity, convert backlog to revenue and normalize free cash flow, the stock should re-rate. If not, the stop at $225 protects capital and limits exposure to a valuation re-pricing.

Key near-dates

• Q3 results and guidance released 10/27/2026 — investor reaction followed through 10/29/2026 as details on capex and FCF drove debate.
• Watch the next quarterly update for signs of backlog conversion and FCF trajectory; two further quarterly prints within the 180-day horizon will be decisive.

Final thought

This is a high-conviction trade with built-in execution risk. Enter at $260, keep a tight stop at $225, and give management time to prove the $40B roadmap. If they do, you’ll be sitting on a large upside; if they don’t, the stop protects you from a painful multiple contraction.